Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QLC5513 + QL1706
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
QLC5513 + QL1706 is a combination therapy being investigated for the treatment of advanced or metastatic triple-negative breast cancer (TNBC). QLC5513 is an antibody-drug conjugate (ADC) targeting Trophoblast cell-surface antigen 2 (Trop2), utilizing a proprietary stable linker and an SN38 (a topoisomerase I inhibitor) cytotoxic payload. QL1706 (epalolimab tovolimab) is a first-in-class bifunctional Mab-like protein (Mab-Pair) that simultaneously targets Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4). This combination aims to leverage the targeted cytotoxicity of the ADC with the dual immune checkpoint inhibition of QL1706 to enhance anti-tumor activity in patients who have received prior systemic therapy.
- Other names
- QLC5513 + Epalolimab TovolimabQLC5513 + QL1706-Fudan University-triple-negative breast cancer
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on QLC5513 + QL1706.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLC5513 + QL1706.